![]() |
|
|
From the Department of Pharmacology, the University of Michigan Medical School, Ann Arbor, Michigan
(Received January 24, 2003; accepted April 9, 2003)
| Abstract |
|---|
|
|
|---|
The inhibitory effects of cigarette constituents and cigarette smoke on
biologically available NO have also been extended to cellular and animal
models. Extracts of cigarette smoke cause a time- and dose-dependent loss of
eNOS activity and eNOS protein in pulmonary artery endothelial cells
(Su et al., 1998
). Exposure of
rats to cigarette smoke causes a decrease in nNOS activity and nNOS protein in
penile tissue while leaving eNOS protein unchanged
(Xie et al., 1997
). A loss of
nNOS protein in rat brainstem was observed after prenatal exposure to
cigarette smoke (Hasan et al.,
2001
), although no loss of nNOS protein was found in adult rat
lung (Wright et al., 1999
).
Thus, it appears that smoking can lead to a selective loss of NOS activity and
protein depending on the conditions and tissues; however, the mechanism by
which this activity and protein are lost is not known.
We wondered if there is a direct interaction of some of the chemicals
present in cigarettes with NOS. In the current study, we examined whether
chemicals found in cigarette smoke or in the cigarette itself could directly
inhibit nNOS and the mechanism by which this occurs. We have discovered, with
the use of an in vitro system containing purified nNOS, that aqueous extract
of cigarette or cigarette smoke inactivates nNOS in a time- and
metabolism-based manner. The active entity is a low molecular weight,
charcoal-extractable, water-soluble, nonvolatile compound(s). The compound is
not nicotine. In that other metabolism-based inactivators of nNOS have been
shown to lead to enhanced proteasomal degradation of nNOS
(Osawa et al., 2003
), the
inactivation of the enzyme by cigarette constituents in a metabolism-based
manner may explain the loss of nNOS protein associated with inhalation of
cigarette smoke. Thus, this discovery of a direct mechanism of inactivation of
nNOS and the nature of the cigarette constituents responsible for this
inactivation may aid in understanding some of the biochemical changes
associated with smoking.
| Materials and Methods |
|---|
|
|
|---|
Methods. Preparation of cigarette smoke extract (CSE) and
cigarette extract (CE). For preparation of CSE, cigarette smoke was
generated and bubbled through 10 ml of water at room temperature as described
(Su et al., 1998
). Each
cigarette was burned over a 3 to 4 min duration with the use of a house vacuum
line. Typically, 10 cigarettes were burned in series to make the stock
solution of smoke extract, which was stored at 4°C. In the case of Accord
cigarettes, the same vacuum apparatus was used, but the cigarettes were placed
in the heating apparatus as instructed by the manufacturer to generate the
smoke. For preparation of CE, four cigarettes were cut open and the contents
were ground with a mortar and pestle and subsequently transferred to a 50-ml
plastic tube containing 40 ml of water. The tube was placed on a rotator mixer
for 24 h at room temperature. The contents were passed through cheesecloth,
and the liquid portion was spun at 2,000g for 4 min. The supernatant
was vacuum-filtered with the use of a glass-fritted filter, initially with a
coarse mesh (40 to 60 µm) and then subsequently with a fine mesh (4 to 5.5
µm) filter. The clear solution was stored at 4°C.
Treatment of CSE and CE. To determine the acid/base characteristics of the inactivator, a series of extractions with organic solvent under acidic and basic conditions was performed. A solution of HCl (6 N) was added to 50 ml of CSE or CE until the pH was approximately 2. This solution was subsequently extracted with an equal volume of methylene chloride. The organic fraction was further extracted with an equal volume of 1 N NaOH to give an organic fraction (Fraction 1) and an aqueous fraction (Fraction 2). The aqueous fraction from the original acidic extraction was made basic (pH 10) with 2 N NaOH and then extracted with an equal volume of methylene chloride. This gave an organic fraction (Fraction 3) and an aqueous fraction (Fraction 4). The organic fractions were dried with Na2SO4, flash evaporated, and the residue brought up in 1 ml of ethanol and stored at 4°C. The aqueous fractions were immediately neutralized with 6 N HCl, put under a vacuum to remove residual methylene chloride, and stored at 4°C. For testing in nNOS assays described below, the ethanol solution was added to glycerol (10% as a final concentration in the reaction mixture) and the ethanol removed by a gentle stream of nitrogen.
To test for volatility of the inactivator, we placed 3-ml aliquots of CSE or CE into glass vials, which were placed in a SpeedVac (Thermo Savant, Holbrook, NY), and dried to completeness (approximately 12 h). The residue was reconstituted in 3 ml of water and tested for its ability to inactivate nNOS as described below. We also determined whether the inactivator(s) would pass through a Centricon (Amicon, 3,000 molecular weight cut-off; Millipore Corporation, Bedford, MA) filter. A 5-ml aliquot of CE or CSE was placed in the Centricon filter and processed according to the manufacturer's instructions. The filter was spun at 3,000g for 4 h at 4°C. The retentate was reconstituted to a final volume of 5 ml with water. An aliquot (144 µl) of the filterate, retentate, or starting material was tested for its ability to inactivate nNOS by the use of the oxyhemoglobin assay described below.
The nature of the inactivator(s) was also tested by ion-exchange chromatography. CE (1 ml) was loaded onto a cation exchange column (Bio-Rad AG 50W-X8, sodium form, loaded in a 5 3/4 inch disposable pasteur pipette with a glass wool plug; Bio-Rad, Hercules, CA) equilibrated with water. The column was washed with water (2 ml) and then washed with 2M NaCl (1 ml). Fractions were collected from the flow-through, water wash, and salt wash steps. In other studies, CE was treated with an anion exchange column (Bio-Rad AG1-X10, chloride form) instead of the cation exchange column. The CE was also tested for binding to activated charcoal. An aliquot (250 µl) of a mixture of activated charcoal (5% w/v) was placed in an Eppendorf tube and spun (16,000g) on a microcentrifuge for 5 min. The water was taken off and 500 µl of CE was added, and the tube was placed on a rotator for 30 min. The mixture was spun down again and the supernatant was tested for the presence of the inactivator.
Expression and purification of nNOS. nNOS was overexpressed in Sf9
insect cells as previously described
(Bender et al., 1999
).
Oxyhemoglobin (25 µM) was added as a source of heme during expression.
Cells were harvested and suspended in 1 volume of 10 mM Hepes, pH 7.5,
containing 320 mM sucrose, 100 µM EDTA, 0.1 mM dithiothreitol, 10 µg/ml
trypsin inhibitor, 100 µM leupeptin, 2 µg/ml of aprotinin, 6 mM
phenylmethanesulphonyl fluoride, and 10 µM BH4, and the
suspended cells were ruptured by Dounce homogenization. Lysates from infected
Sf9 cells (8 x 109) were centrifuged at 100,000g for
1 h. The supernatant fraction was loaded onto a 2'5'-ADP Sepharose
column (8 ml), and the nNOS was affinity purified as described
(Roman et al., 1995
), except
that 10 mM 2'-AMP in high salt buffer was used to elute the protein. The
nNOS-containing fraction was concentrated with the use of a Centriplus YM-10
concentrator (Amicon, 10,000 molecular weight cut-off; Millipore Corporation)
to 10 ml and loaded onto a Sephacryl S-300 HR gel filtration column (2.6
x 100 cm; Amersham Biosciences Inc., Piscataway, NJ, equilibrated with
50 mM Tris-HCl, pH 7.4, containing 100 mM NaCl, 10% glycerol, 0.1 mM EDTA, 0.1
mM dithiothreitol, and 5 µM BH4. The proteins were eluted at a
flow rate of 1.0 ml/min, and 1.0-ml fractions were collected and analyzed for
protein content and NOS activity. The fractions containing NOS activity were
pooled and supplemented with 10 µM BH4 and concentrated with the
use of a Centriplus YM-10 concentrator (Millipore Corporation). This
Sephacryl-purified nNOS preparation has a specific activity of 1150
nmol/min/mg of protein and was stored at 80°C.
Treatment of nNOS with inactivator(s) and nNOS activity assay.
Purified nNOS (80 µg/ml) was added to a "first reaction
mixture" of 40 mM potassium phosphate, pH 7.4, containing 0.2 mM
CaCl2, 500 unit/ml superoxide dismutase, 100 units/ml catalase, 80
µg/ml crude calmodulin, 100 µM BH4, 1 mM dithiothreitol, the
desired concentration of extract, and an NADPH-generating system composed of
0.4 mM NADP+, 10 mM glucose 6-phosphate, and 1 unit of glucose
6-phosphate dehydrogenase/ml, expressed as final concentrations, in a total
volume of 180 µl. In control samples, we have omitted the cigarette extract
from the first reaction mixture described above. After incubation at 30°C,
aliquots (10 µl) of the first reaction mixture were transferred to an
"oxyhemoglobin assay mixture" containing 200 µM
CaCl2, 250 µM L-arginine, 100 µM BH4,
100 units/ml catalase, 10 µg/ml crude calmodulin, 25 µM oxyhemoglobin,
and an NADPH-generating system composed of 0.4 mM NADP+, 10 mM
glucose 6-phosphate, and 1 unit of glucose 6-phosphate dehydrogenase/ml,
expressed as final concentrations, in a total volume of 190 µl of 40 mM
potassium phosphate, pH 7.4. The assay mixture was incubated at 37°C, and
the rate of NO-mediated oxidation of oxyhemoglobin was monitored by measuring
the absorbance at
401 nm 411 nm with a microtiter plate reader
(SpectraMax Plus, Molecular Devices Corp., Sunnyvale, CA). The rate was
determined from the linear portion of the time-dependent changes in
absorbance. In studies where NO synthesis was measured by the use of
radiolabeled arginine, aliquots (10 µl) of the first reaction mixture were
transferred to a "14C-arginine assay mixture"
containing 100 µM L-arginine (22 mCi/mmol), 200 µM
CaCl2, 100 µM BH4, 100 units/ml catalase, 10 µg/ml
calmodulin, and an NADPH-generating system composed of 0.4 mM
NADP+, 10 mM glucose 6-phosphate, and 1 unit of glucose 6-phosphate
dehydrogenase/ml, expressed as final concentrations, in a total volume of 100
µl of 40 mM potassium phosphate, pH 7.4. The assay mixture was incubated at
37°C for 5 min, and the amount of radiolabeled citrulline was
quantified.
| Results |
|---|
|
|
|---|
|
|
Effects of NADPH, Arginine, and Asymmetric Dimethyl-L-arginine (NG,NG-dimethyl-L-arginine) on the Time-Dependent Inactivation of nNOS by CE. To further investigate the nature of the time-dependent inactivation of nNOS, we added or deleted cofactors and substrates in the first reaction mixture (Fig. 3). The absence of calmodulin (condition 2) or NADPH (condition 3) prevented the inactivation due to CE, suggesting that a metabolically capable enzyme was needed for the inactivation to occur. The inclusion of L-arginine (condition 4), but not D-arginine (condition 5), protected the enzyme from inactivation due to CE suggesting that the inactivation is an active site-directed process. Furthermore, asymmetric dimethyl-L-arginine (ADMA, condition 6), which is a competitive NOS inhibitor acting on the substrate binding site, could also protect the enzyme from inactivation. A competitive inhibitor will decrease the metabolism of the mechanism-based inactivator and since metabolic activation of the inactivator is necessary for formation of the reactive intermediate, which inactivates the enzyme, the overall effect should be protection of the enzyme by the inhibitor.
|
Partial Characterization of the Inactivator in CE. To investigate whether the nNOS inactivator(s) is volatile we placed CE under vacuum and took the sample to dryness by the use of a SpeedVac apparatus and then reconstituted the sample with water. As shown in Table 1, this SpeedVac evaporated and then reconstituted sample was able to inactivate nNOS just as well as the original solution of CE that was not dried (none), indicating that the compound(s) responsible for inactivating nNOS is nonvolatile. Next, we investigated if the inactivator(s) is a high or low molecular mass compound(s). The CE was passed through a 3,000 molecular weight cut-off membrane, and the flow-through fraction (filtrate) was found to contain the inactivator whereas the retained fraction (retentate), which was made to the original volume with water and tested, did not contain the inactivator. This indicates that the inactivator(s) is a compound(s) of relatively low molecular mass. As shown in Table 1, the CE was extracted with methylene chloride under acidic and basic conditions to generate four fractions. These fractions were assessed for the presence of the inactivator(s) and compared with the original starting material. As might be expected from the water soluble-nature of the compounds, nearly all the inactivator(s) remained in the aqueous phase throughout the extraction procedure and ended up in Fraction 4. As shown in Table 1, we also found that the inactivator(s) in CE was bound to a column containing a cation exchange resin as evidenced by the lack of inactivation caused by the flow-through fraction. This was confirmed as the inactivator(s) was eluted off the column with 2 M NaCl. On the other hand, the inactivator(s) did not bind to an anion exchange resin and indicates that the compound(s) are either not anionic or only weakly anionic so as it could not displace the chloride ions on the resin. The small size, water solubility, and cationic nature suggested that the inactivator may be a small hydrophilic organic compound or perhaps a metal. To try to differentiate from these possibilities, we treated CE with activated charcoal for 30 min, and the sample was spun, and the supernatant was examined. We found that the inactivator(s) was bound to charcoal as judged by the lack of inactivation caused by the supernatant. Thus, the inactivator is likely an organic, small molecular mass, cationic compound(s). Heating of CE in boiling water for 5 min had no effect on the ability of the CE to inactivate nNOS.
|
Last, we tested research reference cigarettes obtained from the Tobacco and
Health Research Institute, University of Kentucky (Lexington, KY). These
cigarettes were produced as a reference standard for comparing data. As shown
in Fig. 4, cigarette 4A1
(
, dashed line) and cigarette 1R3 (
, dotted line) caused a
dose-dependent inactivation of nNOS with an IC50 of 0.008 and 0.005
cigarette equivalents, respectively. The commercial grade Camel cigarettes
(
, solid line) are shown for comparison with an IC50 of
0.005. The 4A1 cigarettes are similar to the 1R3 cigarettes except that 4A1
has a much lower nicotine content. This difference, however, was not the cause
of the greater potency of the 4A1 cigarette as nicotine, up to a concentration
of 1.0 mM, did not inactivate nNOS (inset).
|
| Discussion |
|---|
|
|
|---|
The mechanism of inactivation may be of importance in understanding why the
nNOS protein is decreased in penile (Xie
et al., 1997
) and brain tissue
(Hasan et al., 2001
) after
exposure of rats to smoke. The accelerated degradation of nNOS has been
observed with several other metabolism-based NOS inhibitors, including
NG-methyl-L-arginine,
N5-(1-iminoethyl)-L-ornithine, and guanabenz
(Nakatsuka et al., 1998
;
Noguchi et al., 2000
). The
loss of nNOS activity per se is not the signal for proteolytic removal since
reversible inhibitors such as
NG-nitro-L-arginine and 7-nitroindazole did not
enhance degradation of nNOS and may have actually stabilized the protein
(Nakatsuka et al., 1998
;
Noguchi et al., 2000
). There
is precedence for metabolism-based or suicide inactivators to cause the
enhanced proteolytic turnover of the affected enzyme. Especially pertinent are
the examples described below from the liver microsomal cytochrome P450
enzymes, which are related to NOS (Alderton
et al., 2001
). It appears that structural changes and not the
functional inactivation per se is the "trigger" for proteolysis of
liver microsomal P450 cytochromes (Correia
et al., 1987
; Tierney et al.,
1992
). Moreover, the crosslinking of heme to protein plays a major
role in the proteolytic recognition, whereas covalent alteration of the heme
or the protein do not appear to be involved
(Tierney et al., 1992
;
Korsmeyer et al., 1999
;
Wang et al., 1999
). Indeed for
nNOS one of the established targets of reactive intermediates is the heme
prosthetic group, which is covalently altered to form heme adducts, including
those crosslinked to the protein
(Jianmongkol et al., 2000
;
Vuletich et al., 2002
). For
example, heme alteration and protein alteration occurs for
NG-methyl-L-arginine and
N5-(1-iminoethyl)-L-ornithine
(Olken et al., 1994
;
Bryk and Wolff, 1999
).
The nature of the constituent or constituents that are responsible for inactivating nNOS is still unknown. We have, however, ruled out nicotine, CO, and NO by our studies. The inactivator(s) appears to be a low molecular mass, nonvolatile, organic, cationic compound(s). This is not unexpected as the substrates for the enzyme are relatively low molecular mass polar compounds with cationic character. There are over 5,000 chemicals that have been characterized in tobacco smoke, including many with cationic character. It is also not clear if the same inactivator(s) is present in tobacco smoke as well as in the tobacco plant itself as burning may destroy and generate new inactivator(s). Indeed, the effects are more complex in the case of smoke as some competitive inhibitor(s) as well as time-dependent inactivator(s) are present. Interestingly, the smoke extract from the Accord cigarettes, which are heated but not burned, did not give a competitive inhibition of nNOS, suggesting that perhaps burning is needed to produce this type of nNOS inhibitor(s). We aim to delineate the exact chemical nature of the compounds that are responsible for these effects as unique inhibitors may be identified.
A dysfunctional eNOS is evident in smokers
(Kharitonov et al., 1995
;
Higman et al., 1996
;
Heitzer et al., 2000
;
Barbera et al., 2001
), and it
is likely that eNOS is also directly inactivated by cigarette constituents.
The results of Xie et al.
(1997
) indicate that tobacco
smoke has a preferential effect on nNOS over eNOS in the penile tissue,
although the mechanism of this selectivity is unknown. Perhaps there is a
selective inactivation of nNOS over eNOS in this tissue. The further study of
the mechanism of action of tobacco constituents is needed to better understand
this selectivity and the complex actions of tobacco smoking on NO
synthesis.
| Acknowledgments |
|---|
| Footnotes |
|---|
1 These authors are both considered first authors. ![]()
2 Trainee under Pharmacological Sciences Training Program GM07767 from the
National Institutes of Health. ![]()
3 Abbreviations used are: NO, nitric oxide; NOS, nitric-oxide synthase; nNOS,
neuronal NOS; eNOS, endothelial NOS; BH4,
(6R)-5,6,7,8-tetrahydro-L-biopterin; CSE, the water
extract made from cigarette smoke; CE, the water extract made directly from
the nonburned cigarette; CAM, calmodulin; ASE, Accord smoke extracts; LSE,
Lattuca sativa smoke extracts; ADMA, asymmetric
dimethyl-L-arginine. ![]()
Address correspondence to: Yoichi Osawa, Department of Pharmacology, The University of Michigan Medical School, 1301 Medical Science Research Building III, Ann Arbor, MI 48109-0632. Email: osawa{at}umich.edu
| References |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
W.-Z. Zhang, K. Venardos, J. Chin-Dusting, and D. M. Kaye Adverse Effects of Cigarette Smoke on NO Bioavailability: Role of Arginine Metabolism and Oxidative Stress Hypertension, August 1, 2006; 48(2): 278 - 285. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. R. Lowe, A. C. Everett, A. J. Lee, M. Lau, A. Y. Dunbar, V. Berka, A.-l. Tsai, and Y. Osawa TIME-DEPENDENT INHIBITION AND TETRAHYDROBIOPTERIN DEPLETION OF ENDOTHELIAL NITRIC-OXIDE SYNTHASE CAUSED BY CIGARETTES Drug Metab. Dispos., January 1, 2005; 33(1): 131 - 138. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||